4,552 publications from this institution
Under the leadership of the author, the Rega Institute, which celebrated its fiftieth anniversary in 2004, has grown to be a world-renowned center for research on nucleoside analogues, antivirals, anti-HIV drugs, cytokines, and chemokines. Today it is one of the world's leading academic centers for antiviral research. This section talks about the 1983 description of the synthesis and antiviral properties of aminoacyl esters of acyclovir, which led to the development of the valyl ester (valacyclovir) for the oral treatment of herpes simplex virus (HSV) and VZV infections, and also talks about the 1985 description of the principle of combined gene therapy/chemotherapy of cancer by using antiviral agents such as ganciclovir and BVDU that are highly and specifically cytostatic to tumor cells transfected by the HSV-1 (HSV-2 or VZV) thymidine kinase gene. The collaborative centers are located in five continents and help to establish and maintain a leading position in the field. The author's most tangible and most rewarding contributions are his discoveries that have led to a panoply of new antiviral drugs that have met medical needs and helped alleviate the symptoms, if not saved the lives, of patients suffering from the most severe and often life-threatening viral infections.
Melanoma growth stimulatory activity (MGSA) is a mitogenic protein secreted by Hs294T melanoma cells that corresponds to the polypeptide encoded by the human gro gene. The MGSA/gro cDNA has been expressed in mammalian cells and the secreted recombinant factor has been purified. Biochemical and biological characterization shows that the recombinant protein is identical with the natural protein and is devoid of posttranslational glycosylation, sulfation, and phosphorylation. The two C-terminal amino acids are proteolytically removed from the mature recombinant MGSA, indicating a length of 71 instead of the predicted 73 amino acids. The recombinant MGSA is mitogenically active on the Hs294T melanoma cells. The purified MGSA competes with interleukin 8 for binding to neutrophil receptors and exhibits neutrophil chemotactic activity equivalent to that of interleukin 8.
Abstract Aus der racemischen Säure erhält man die Ester (I), die gegen verschiedene Viren (Vaccinia, Parain?uenza, Polio etc.) aktiv sind.